Chemistry journal issues correction longer than original paper

A 2011 chemistry paper required corrections so extensive that the author published the changes as a second, longer paper.

Both papers, published in the Chinese Journal of Chemistry, described the synthesis of a protein molecule with potential therapeutic applications in cancer. But when the paper’s corresponding author Yikang Wu tried to continue the work, he discovered that a substantial part of the 2011 study was incorrect.

The original paper is not marked with any editor’s note, even though the new paper — which is three pages longer than the 2011 version — acknowledges it is a “partial retraction/correction of previous results.” The new paper does appear in the list of “related content” for the 2011 article.

Given the errors, in the 2017 paper, Wu and his co-authors write: Continue reading Chemistry journal issues correction longer than original paper

Two more retractions for former US prof who altered dozens of images

Two journals have retracted papers by a biologist who was recently found guilty of misconduct by his former employer, the University of Colorado Denver, bringing the total to five.

The investigation report by UC Denver, which we obtained earlier this year via a public records request, had recommended one of the two newest retractions, which appears in the journal Hepatology. The other retraction, in the Journal of Immunology, was not flagged by the report — which found, among other conclusions, that Almut Grenz had altered multiple values in research that had already been submitted for peer review.

Here’s the notice for the Journal of Immunology paper:

Continue reading Two more retractions for former US prof who altered dozens of images

Former MD Anderson researcher objects to retraction of his paper

A cell biology journal has retracted a 2016 paper after an investigation revealed that the corresponding author failed to include two co-authors and acknowledge the funding source.

According to the retraction notice, the Journal of Cellular Physiology retracted the paper after the University of Texas, MD Anderson Cancer Center found that last author Jin Wang had omitted two researchers from the list of authors, and had also failed to acknowledge funding from the U.S. National Institutes of Health (NIH).

But Wang tells a different story. Continue reading Former MD Anderson researcher objects to retraction of his paper

Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Earlier this year, a raging controversy regarding a new drug spilled into the pages of a leading medical journal: the head of the U.S. Food and Drug Administration and another official publicly called for the retraction or correction of a peer-reviewed article about the drug. They didn’t get their wish. Now, documents released by the FDA via a lawsuit shed light on the attempt — and show how tricky it can be to correct the official record.

The controversy surrounds the approval of eteplirsen, a drug approved last September to treat Duchenne Muscular Dystrophy, a rare but invariably fatal disease that strikes (mostly) young boys. Eteplirsen was approved over the objections of the FDA team that reviewed the drug, which determined that there was insufficient evidence to approve the drug.

But the controversy didn’t end within the walls of the FDA complex. Ellis Unger, who led the review team, believed that one of the principal studies of the drug, published in the Annals of Neurology, was “misleading” because it was based on “unreliable data.” So in early November, Unger, joined by the then-head of the FDA, Robert Califf, took the extremely rare move of writing to the editor of the journal to “urge that the paper be corrected or retracted….”

According to the documents, the authors of the Annals article did, in fact, agree to correct the article.

On November 9, 2016, Clifford Saper, Annals‘ editor in chief, wrote to Califf and Unger:

Continue reading Released FDA docs reveal details of agency’s (failed) attempt to retract paper

Uni dings schizophrenia studies for problems with informed consent, other flaws

Psychiatry journals have retracted two papers evaluating a schizophrenia drug after a university in Japan flagged issues, such as a lack of written informed consent.

The papers—published in Human Psychopharmacology: Clinical & Experimental in 2012 and Psychiatry and Clinical Neurosciences in 2014—examined the safety and effectiveness of an antipsychotic drug in patients with schizophrenia.

According to the retraction notice in Psychiatry and Clinical Neurosciences, the ethics committee at St. Marianna University School of Medicine in Kawasaki found that “the trial included subjects who did not satisfy inclusion criteria.” For instance, not all patients provided written informed consent. But the university found no evidence for data falsification or fabrication.

A spokesperson for Human Psychopharmacology told us: Continue reading Uni dings schizophrenia studies for problems with informed consent, other flaws

Want to appeal a journal’s rejection? Sure — that’ll be $700

Different journals follow different editorial policies — but we’ve never seen any charge money to authors who want to appeal an editorial decision. Until now.

Recently, a criminal justice researcher sent us links to multiple journals that charge appeal fees. For instance, the Journal of Accounting Research says authors must pay $500 for each submission — and another $500 if they want the journal to reconsider its decision to reject the paper.

Under “Appeals,” the journal writes:

Continue reading Want to appeal a journal’s rejection? Sure — that’ll be $700

More notices appear for embattled Cornell food researcher

Journals have posted two corrections alongside papers by Brian Wansink, a food researcher whose work has lately come under fire.

One of the corrected papers was among the initial batch that raised eyebrows last year; after Wansink praised the productivity of one of his researchers, critics suggested four papers contained critical flaws. The questions about his work soon extended to other papers, one of which was retracted in April. That month, an internal review by Cornell University announced that Wansink made numerous mistakes, but did not commit misconduct. Wansink has pledged to reanalyze multiple papers.

One paper that was among those initially criticized has received a formal correction notice from the Journal of Product & Brand Management. The notice, which appears behind a paywall, has drawn fire from a regular critic of Wansink’s work, Jordan Anaya, who argues “this correction actually needs a correction, actually several.”

Here’s the notice for “Peak-end pizza: prices delay evaluations of quality:”

Continue reading More notices appear for embattled Cornell food researcher

Are there foxes in Tasmania? Follow the poop

Stephen Sarre, based at the University of Canberra in Australia, has made a career out of collecting and analyzing poop.

It’s a tough job, but someone’s got to do it. Part of his work is designed to answer a multi-million dollar question: Is Tasmania home to foxes, a pest that carries rabies and other diseases and can ravage local wildlife? According to the Australian news outlet ABCthe Tasmanian and Australian governments have spent $50 million (AUD) on hunting foxes on the island since 2001 — even though many have debated whether they are even there.

In 2012, after analyzing thousands of fecal samples, Sarre published a paper in the Journal of Applied Ecology which boldly claimed that “Foxes are now widespread in Tasmania.” But many outside researchers didn’t buy it, and quickly voiced their criticisms of the paper, namely that there may be problems with false positives and the methodology used to analyze the samples. Recently, the journal issued an expression of concern for the paper, citing an ongoing investigation into the allegations.

Here’s the expression of concern (paywalled, tsk tsk):

Continue reading Are there foxes in Tasmania? Follow the poop

The retraction countdown: How quickly do journals pull papers?

After Tina Wenz was found guilty of scientific misconduct, how long did it take for journals to retract the problematic papers?  The answer: Between three and nine months.

In September 2016, the University of Cologne found that Wenz had committed scientific misconduct in six papers and requested they all be retracted. From that point on, the retraction clock was ticking.

We’ve explored how long it takes a journal to act over the years, and we’ve found that the time between identifying a problem to retracting the paper can vary — and sometimes last years.

In Wenz’s case, one of the papers—published in Cell Metabolism in 2009—had already been retracted in 2015. Three of the remaining five were retracted in December 2016—a 2008 paper in Cell Metabolism, a 2009 paper in Proceedings of the National Academy of Sciences (PNAS), and a 2009 paper in the Journal of Applied Physiology.

In January 2017, the journal IUBMB Life pulled a 2014 paper flagged in the investigation. And just over nine months after Wenz was found guilty of misconduct, the last paper—published in 2013 in Mitochondrion—has been retracted.

The most recent notice states that the University of Cologne requested the retractions, after determining that the data had been “inappropriately manipulated.”

Here’s the retraction notice in Mitochondrion:

Continue reading The retraction countdown: How quickly do journals pull papers?

Inclusion of “personal correspondence” in evolution paper prompts retraction, new journal policy

Hearsay is not admissible as evidence in court — and it doesn’t seem to go very far in science, either.

A pair of researchers in the field of human evolution have lost a paper which contained data from “personal correspondence” that the providing party apparently did not enjoy seeing in print.

The article, “Early hominin biogeography in Island Southeast Asia,” was published in the September/October 2015 issue of Evolutionary Anthropology. The authors, Roy Larick and Russell Ciochon, are paleoanthropologists and co-founders of the Iowa-Bandung Java Project — a 20-year old collaborative effort to study the origins of early humans in Indonesia. Continue reading Inclusion of “personal correspondence” in evolution paper prompts retraction, new journal policy